{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:23:20Z","timestamp":1787844200394,"version":"build-2784847793"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>An acute attack of migraine, incapacitates the migraineurs, and is widely prevalent. And to warden off its symptoms, recently two groups of drugs have been approved and launched.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The aim of this systematic review and indirect meta-analysis is to evaluate and summarize the effectiveness of these pharmacological interventions in managing the aforesaid disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and Methods:<\/jats:title>\n                    <jats:p>An extensive literature search was done through Cochrane library, Pub Med, clincialtrials.gov, for a period of 5 years (2015\u20132020), using key words: lasmiditan; ubrogepant; rimegepant; and acute migraine. Randomized double-blind phase III clinical trials, published in English language, were included which explored the efficacy and safety of these drugs. The outcomes of this meta-analysis included proportion of patients' headache, most bothersome symptoms free, and no disability at all at 2 h post-dose, with sustained pain freedom 2-24 h, and experiencing any adverse event. An indirect network meta-analysis was also conducted to determine the comparative effectiveness of these drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of seven RCTs involving 7266 patients were included. In general, the new drugs demonstrated better result in all the efficacy parameters. The adverse events were observed in treatment group compared to placebo. While in the indirect comparison, lasmiditan emerged to be superior in all the outcomes, except for sustained pain freedom 2-24 h (rimegepant was better). The adverse events were more with lasmiditan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>All the newer drugs have shown significant improvement in the outcomes analyzed. Lasmiditan appears to be superior among the newer drugs in efficacy; however it has more adverse effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0028-3886.315991","type":"journal-article","created":{"date-parts":[[2021,5,16]],"date-time":"2021-05-16T04:19:32Z","timestamp":1621138772000},"page":"S43-S50","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Ditans vs Gepants"],"prefix":"10.4103","volume":"69","author":[{"given":"Alok","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhyuti","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20240907","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s40267-019-00664-2","article-title":"Recent and updated pharmacotherapy of migraine","volume":"35","author":"Singh","year":"2019","journal-title":"Drugs Ther Perspect"},{"key":"R4-6-20240907","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/head.13301","article-title":"Migraine burden of disease: From the patient's experience to a socio-economic view","volume":"58","author":"Agosti","year":"2018","journal-title":"Headachen"},{"key":"R5-6-20240907","first-page":"271","article-title":"Treatment of acute migraine headache","volume":"83","author":"Gilmore","year":"2011","journal-title":"Am Fam Physician"},{"key":"R6-6-20240907","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/head.13444","article-title":"The emperor's new Gepants: Are the effects of the new oral CGRP antagonists clinically meaningful?","volume":"59","author":"Tfelt-Hansen","year":"2018","journal-title":"Headache"},{"key":"R7-6-20240907","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1111\/j.1526-4610.1999.00006.x","article-title":"Acute migraine therapy: Do doctors understand what patients with migraine want from therapy?","volume":"39","author":"Lipton","year":"1999","journal-title":"Headache"},{"key":"R8-6-20240907","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.2147\/JPR.S152216","article-title":"Lasmiditan for the treatment of acute migraine: A review and potential role in clinical practice","volume":"11","author":"Oswald","year":"2018","journal-title":"J Pain Res"},{"key":"R9-6-20240907","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s10194-019-1044-6","article-title":"Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: Post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials","volume":"20","author":"Shapiro","year":"2019","journal-title":"J Headache Pain"},{"key":"R10-6-20240907","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1007\/s42399-020-00390-1","article-title":"Acute migraine: Can the new drugs clinically outpace?","volume":"2","author":"Singh","year":"2020","journal-title":"SN Compr Clin Med"},{"key":"R11-6-20240907","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s10194-017-0807-1","article-title":"Blocking CGRP in migraine patients \u2013 A review of pros and cons","volume":"18","author":"Deen","year":"2017","journal-title":"J Headache Pain"},{"key":"R12-6-20240907","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"R13-6-20240907","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: Is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"R14-6-20240907","doi-asserted-by":"crossref","first-page":"e17734","DOI":"10.1097\/MD.0000000000017734","article-title":"The efficacy of dexketoprofen for migraine attack: A meta-analysis of randomized controlled studies","volume":"98","author":"Baohua","year":"2019","journal-title":"Medicine (Baltimore"},{"key":"R15-6-20240907","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R16-6-20240907","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"R17-6-20240907","doi-asserted-by":"crossref","first-page":"F8","DOI":"10.1136\/archdischild-2018-315224","article-title":"Network meta-analysis explained","volume":"104","author":"Dias","year":"2019","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"R18-6-20240907","doi-asserted-by":"crossref","first-page":"e2222","DOI":"10.1212\/WNL.0000000000006641","article-title":"Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study","volume":"91","author":"Kuca","year":"2018","journal-title":"Neurology"},{"key":"R19-6-20240907","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/brain\/awz134","article-title":"Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine","volume":"142","author":"Goadsby","year":"2019","journal-title":"Brain"},{"key":"R20-6-20240907","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","article-title":"Ubrogepant for the treatment of migraine","volume":"381","author":"Dodick","year":"2019","journal-title":"N Engl J Med"},{"key":"R21-6-20240907","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1001\/jama.2019.16711","article-title":"Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: The ACHIEVE II Randomized Clinical Trial","volume":"322","author":"Lipton","year":"2019","journal-title":"JAMA"},{"key":"R22-6-20240907","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","article-title":"Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: A randomised, phase 3, double-blind, placebo-controlled trial","volume":"394","author":"Croop","year":"2019","journal-title":"Lancet"},{"key":"R23-6-20240907","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1811090","article-title":"Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine","volume":"381","author":"Lipton","year":"2019","journal-title":"N Engl J Med"},{"key":"R28-6-20240907","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1111\/head.12150","article-title":"Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: Results of the American Migraine Prevalence and Prevention (AMPP) Study","volume":"53","author":"Buse","year":"2013","journal-title":"Headache"},{"key":"R30-6-20240907","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1111\/head.13858","article-title":"Calcitonin gene-related peptide receptor antagonists (gepants) for the acute treatment of nausea in episodic migraine: A systematic review and meta-analysis","volume":"60","author":"Chan","year":"2020","journal-title":"Headache"},{"key":"R31-6-20240907","doi-asserted-by":"crossref","first-page":"e01701","DOI":"10.1002\/brb3.1701","article-title":"Gepants for abortive treatment of migraine: A network meta-analysis","volume":"10","author":"Hong","year":"2020","journal-title":"Brain Behav"}],"container-title":["Neurology India"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/0028-3886.315991","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:14:12Z","timestamp":1787843652000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0028-3886.315991"}},"subtitle":["A Systematic Review and Indirect Network Meta-Analysis for Comparative Analysis of Efficacy and Safety"],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":24,"journal-issue":{"issue":"Suppl 1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/0028-3886.315991","relation":{},"ISSN":["0028-3886"],"issn-type":[{"value":"0028-3886","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]}}}